GCGR · Company research
General Catalyst Global Resilience Merger Corp. Class A Ordinary Shares (GCGR): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
19records availableOther
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| General Catalyst Global Resilience Merger (GCGR) Stock Price, News & Analysis - MarketBeat | General Catalyst Global Resilience Merger (GCGR) Stock Price, News & Analysis MarketBeat | View source ↗ | MarketBeat | Oct 8, 2026 | neutral | 0 | 0.6 |
| Minerva Humanoids beendet seine Stealth-Phase mit einer von General Catalyst angeführten Pre-Seed-Finanzierungsrunde in Höhe von 10 Millionen US-Dollar, um humanoide Roboter für die gefährlichsten Aufgaben der Welt zu entwickeln | Minerva Humanoids, a robotics company developing semi-autonomous humanoid robots for dangerous tasks in energy and public safety sectors, has completed a $10M pre-seed funding round led by General Catalyst. The company's robot 'Roger' enables trained specialists to remotely operate hazardous missions while remaining safe. Minerva plans to launch commercial pilot projects in fall 2026, with manufacturing based in Western supply chains. | View source ↗ | GlobeNewswire Inc. | Oct 7, 2026 | bullish | 0.75 | 1 |
| Minerva Humanoids sort de l’ombre après une levée de fonds de pré-amorçage de 10 millions de dollars menée par General Catalyst pour la conception de robots humanoïdes destinés aux missions les plus dangereuses au monde | Minerva Humanoids, a robotics startup founded by former MIT CSAIL and Tesla researchers, has raised $10 million in pre-seed funding led by General Catalyst to develop Roger, a semi-autonomous humanoid robot designed for hazardous missions in energy and public safety sectors. The robot enables remote operators to perform dangerous tasks like offshore oil operations and explosive device disposal while remaining physically safe, with the company launching commercial pilot projects in fall 2026. | View source ↗ | GlobeNewswire Inc. | Oct 7, 2026 | bullish | 0.75 | 1 |
| Minerva Humanoids beendet seine Stealth-Phase mit einer von General Catalyst angeführten Pre-Seed-Finanzierungsrunde in Höhe von 10 Millionen US-Dollar, um humanoide Roboter für die gefährlichsten Aufgaben der Welt zu entwickeln | Minerva Humanoids, a robotics company developing semi-autonomous humanoid robots for dangerous tasks in energy and public safety sectors, has completed a $10M pre-seed funding round led by General Catalyst. The company's robot 'Roger' enables trained specialists to remotely operate hazardous missions while remaining safe. Minerva plans to launch commercial pilot projects in fall 2026, with manufacturing based in Western supply chains. | View source ↗ | GlobeNewswire Inc. | Oct 7, 2026 | bullish | 0.75 | 1 |
| Minerva Humanoids sort de l’ombre après une levée de fonds de pré-amorçage de 10 millions de dollars menée par General Catalyst pour la conception de robots humanoïdes destinés aux missions les plus dangereuses au monde | Minerva Humanoids, a robotics startup founded by former MIT CSAIL and Tesla researchers, has raised $10 million in pre-seed funding led by General Catalyst to develop Roger, a semi-autonomous humanoid robot designed for hazardous missions in energy and public safety sectors. The robot enables remote operators to perform dangerous tasks like offshore oil operations and explosive device disposal while remaining physically safe, with the company launching commercial pilot projects in fall 2026. | View source ↗ | GlobeNewswire Inc. | Oct 7, 2026 | bullish | 0.75 | 1 |
| Micot's XTL6001 Featured in Two EASD Presentations: MasR/GCGR/GLP-1R Triple-Agonist Mechanism Opens a Differentiated Path Across Metabolic and Renal Disease - Barchart.com | Micot's XTL6001 Featured in Two EASD Presentations: MasR/GCGR/GLP-1R Triple-Agonist Mechanism Opens a Differentiated Path Across Metabolic and Renal Disease Barchart.com | View source ↗ | Barchart.com | Oct 5, 2026 | neutral | 0 | 0.6 |
| General Catalyst Global Resilience Merger (GCGR) Stock Forecast and Price Target 2026 - MarketBeat | General Catalyst Global Resilience Merger (GCGR) Stock Forecast and Price Target 2026 MarketBeat | View source ↗ | MarketBeat | Sep 16, 2026 | neutral | 0 | 0.6 |
| Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs - The Malaysian Reserve | Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs The Malaysian Reserve | View source ↗ | The Malaysian Reserve | Sep 7, 2026 | neutral | 0 | 0.6 |
| ENHA Stock Price and Chart — NYSE:ENHA - TradingView | ENHA Stock Price and Chart — NYSE:ENHA TradingView | View source ↗ | TradingView | Sep 2, 2026 | neutral | 0 | 0.6 |
| Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model - PR Newswire | Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model PR Newswire | View source ↗ | PR Newswire | Jul 27, 2026 | neutral | 0 | 0.6 |
| Shaanxi Micot Pharmaceutical Technology (SEHK:2335) - Stock Analysis - Simply Wall Street | Shaanxi Micot Pharmaceutical Technology (SEHK:2335) - Stock Analysis Simply Wall Street | View source ↗ | Simply Wall Street | Jun 26, 2026 | neutral | 0 | 0.6 |
| General Catalyst Global Resilience Merger Corp. (GCGR.U) Company Information - Simply Wall Street | General Catalyst Global Resilience Merger Corp. (GCGR.U) Company Information Simply Wall Street | View source ↗ | Simply Wall Street | May 1, 2026 | neutral | 0 | 0.6 |
| General Catalyst Global Resilience Merger Corp. Announces Closing of $402.5 Million Initial Public Offering - Yahoo Finance | General Catalyst Global Resilience Merger Corp. Announces Closing of $402.5 Million Initial Public Offering Yahoo Finance | View source ↗ | Yahoo Finance | May 1, 2026 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Apr 23, 2026 | neutral | 0 | 0.6 |
| Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development - The Manila Times | Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development The Manila Times | View source ↗ | The Manila Times | Nov 30, 2025 | neutral | 0 | 0.6 |
| GLP-1R/GCGR dual agonism dissipates hepatic steatosis to restore insulin sensitivity and rescue pancreatic β-cell function in obese male mice - Nature | GLP-1R/GCGR dual agonism dissipates hepatic steatosis to restore insulin sensitivity and rescue pancreatic β-cell function in obese male mice Nature | View source ↗ | Nature | May 21, 2025 | neutral | 0 | 0.6 |
| HEIGHTS CAPITAL MANAGEMENT, INC - Portfolio Stock Holdings - Quiver Quantitative | HEIGHTS CAPITAL MANAGEMENT, INC - Portfolio Stock Holdings Quiver Quantitative | View source ↗ | Quiver Quantitative | Feb 17, 2025 | neutral | 0 | 0.6 |
| Molecular features of the ligand-free GLP-1R, GCGR and GIPR in complex with Gs proteins | Cell Discovery - Nature | Molecular features of the ligand-free GLP-1R, GCGR and GIPR in complex with Gs proteins | Cell Discovery Nature | View source ↗ | Nature | Feb 13, 2024 | neutral | 0 | 0.6 |
| NeuroBo Pharmaceuticals' Novel GLP1R and GCGR Dual Agonist, DA-1726, Shown to Elicit Superior Weight Loss Efficacy Compared to Semaglutide and Tirzepatide in Preclinical Models - PR Newswire | NeuroBo Pharmaceuticals' Novel GLP1R and GCGR Dual Agonist, DA-1726, Shown to Elicit Superior Weight Loss Efficacy Compared to Semaglutide and Tirzepatide in Preclinical Models PR Newswire | View source ↗ | PR Newswire | Jun 27, 2023 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.